NCM USA   Report issue

For profit Phase 3
Founded: New York NY United States (2010)

Organization Overview

First Clinical Trial
2016
NCT03136328
First Marketed Drug
2014
sodium fluoride (18F)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

NCM USA BRONX LLC

Active Ingredients

Marketed Drugs (3)

ammonia n-13 (2015)

fludeoxyglucose f-18 (2015)

sodium fluoride (18F) (2014)

Drugs in Phase 3 Trials (1)

ga-68-dota-toc (Ga-68-dota-toc) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroendocrine Tumors (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1